BAP1
BAP1 (Ubiquitin carboxyl-terminal hydrolase BAP1) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Mesothelioma, Biliary tract cancer and 5 more.
Overview
Deubiquitinating enzyme that plays a key role in chromatin by mediating deubiquitination of histone H2A and HCFC1. Catalytic component of the polycomb repressive deubiquitinase (PR-DUB) complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-120' (H2AK119ub1). Does not deubiquitinate monoubiquitinated histone H2B.
CIViC holds 19 clinical evidence items and 0 assertions across 10 variants, naming Olaparib, Vorinostat, Valproic Acid and Everolimus and others. Open Targets scores its association with cancer at 0.88 (direct and indirect evidence; datatypes genetic literature 0.89, affected pathway 0.91, literature 0.99, genetic association 0.76, somatic mutation 0.94, animal model 0.38). IntOGen calls it a driver in 23 cohorts (3 activating, 20 loss-of-function), covering Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Cervical Squamous Cell Carcinoma, Cholangiocarcinoma, Oesophageal Adenocarcinoma, Hepatocellular Carcinoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · BAP1 (Ubiquitin carboxyl-terminal hydrolase BAP1) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Mesothelioma, Biliary tract cancer and 5 more.
- 1 · What it is
BAP1 (Ubiquitin carboxyl-terminal hydrolase BAP1) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Mesothelioma, Biliary tract cancer and 5 more.
- 2 · What goes wrong in cancer
Deubiquitinating enzyme that plays a key role in chromatin by mediating deubiquitination of histone H2A and HCFC1.
- 3 · How drugs use it
No product in this corpus aims at BAP1 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:950 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q92560 (protein name, function text, keywords and locations (REST API)); CIViC gene BAP1 (19 evidence items, 0 assertions, 10 variants; diseases: Malignant Mesothelioma, Clear Cell Renal Cell Carcinoma, Uveal Melanoma, Malignant Pleural Mesothelioma, Meningioma and 2 more (GraphQL API, CC0)); Open Targets ENSG00000163930 (association with cancer (MONDO_0004992) 0.88; per-cancer scores at or above 0.5: gastric cancer 0.54, hepatocellular carcinoma 0.53, cholangiocarcinoma 0.50, renal cell carcinoma 0.68, melanoma 0.82, malignant mesothelioma 0.68 (GraphQL API, CC0)); IntOGen BAP1 (driver in 23 cohorts (Act 3, LoF 20); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Deubiquitinating enzyme that plays a key role in chromatin by mediating deubiquitination of histone H2A and HCFC1. Catalytic component of the polycomb repressive deubiquitinase (PR-DUB) complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-120' (H2AK119ub1). Does not deubiquitinate monoubiquitinated histone H2B. The PR-DUB complex is an epigenetic regulator of gene expression and acts as a transcriptional coactivator, affecting genes involved in development, cell communication, signalling, cell proliferation and cell viability. Antagonises PRC1 mediated H2AK119ub1 monoubiquitination. As part of the PR-DUB complex, associates with chromatin enriched in histone marks H3K4me1, H3K4me3, and H3K27Ac, but not in H3K27me3. Location: Cytoplasm; Nucleus; Chromosome (UniProt). Locus 3p21.1 (HGNC).
- Renal cell carcinoma: Open Targets association 0.68 with renal cell carcinoma (MONDO_0005086); CIViC evidence names this disease
- Mesothelioma: Open Targets association 0.68 with malignant mesothelioma (MONDO_0006292); CIViC evidence names this disease
- Biliary tract cancer: Open Targets association 0.64 with biliary tract cancer (MONDO_0003060)
- Hepatocellular carcinoma: Open Targets association 0.53 with hepatocellular carcinoma (MONDO_0007256); IntOGen driver in 3 cohorts (HCC)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.54 with gastric cancer (MONDO_0001056); IntOGen driver in 1 cohort (STAD)
- Breast cancer: IntOGen driver in 1 cohort (BRCA)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 14 therapies; IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 20 cohorts; CIViC holds 19 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Malignant Mesothelioma; Renal Carcinoma.
Latest papers
topQuery for this target: (TITLE:"BAP1" OR ABSTRACT:"BAP1" OR TITLE:"BRCA1 associated deubiquitinase 1" OR ABSTRACT:"BRCA1 associated deubiquitinase 1" OR TITLE:"Ubiquitin carboxyl-terminal hydrolase BAP1" OR ABSTRACT:"Ubiquitin carboxyl-terminal hydrolase BAP1" OR TITLE:"hucep-6" OR ABSTRACT:"hucep-6" OR TITLE:"KIAA0272" OR ABSTRACT:"KIAA0272" OR TITLE:"UCHL2" OR ABSTRACT:"UCHL2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BAP1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPBRM1
Shares Biliary tract cancer (all types), Mesothelioma, Renal cell carcinoma, Oesophageal cancer.
- TargetMAP2K4
Shares Biliary tract cancer (all types), Oesophageal cancer, Hepatocellular carcinoma, Breast cancer (all types).
- TargetCDH11
Shares Biliary tract cancer (all types), Oesophageal cancer, Hepatocellular carcinoma, Breast cancer (all types).
- TargetFAT4
Shares Mesothelioma, Oesophageal cancer, Hepatocellular carcinoma, Breast cancer (all types).
- TargetFOXP1
Shares Biliary tract cancer (all types), Oesophageal cancer, Breast cancer (all types), CIViC.
- TargetFGFR4
Shares Biliary tract cancer (all types), Hepatocellular carcinoma, Breast cancer (all types), CIViC.
- TargetARID2
Shares Biliary tract cancer (all types), Oesophageal cancer, Hepatocellular carcinoma, CIViC.
- TargetPALB2
Shares Biliary tract cancer (all types), Breast cancer (all types), CIViC, IntOGen.